Aboleris Holdco
- Address
- Rue Antoine De Saint-Exupery 14
Sponsor Overview
Specializations
Oncological Therapeutics
The sponsor demonstrates a focused commitment to advancing cancer treatment through targeted therapeutic interventions. Research efforts concentrate on developing novel pharmaceutical approaches for patients with solid tumors, with particular emphasis on addressing advanced malignancies where conventional treatment options may be limited.
- Solid Tumor Treatment Development
- Advanced Cancer Therapeutics
- Oncology Drug Innovation
The organization's research portfolio reflects a dedication to expanding treatment possibilities for patients facing challenging oncological diagnoses, contributing to the broader field of cancer pharmacotherapy through systematic clinical investigation.
Precision Medicine and Targeted Therapy
Investigation into biomarker-driven treatment strategies forms a core component of the sponsor's research framework. The clinical program incorporates advanced patient selection methodologies based on specific molecular characteristics and genetic profiles, ensuring therapeutic interventions are directed toward populations most likely to benefit from targeted approaches.
- Biomarker-Based Patient Selection
- Molecular Profiling Integration
- Personalized Treatment Strategies
This precision-focused approach aligns with contemporary trends in individualized medicine, where treatment decisions are informed by detailed understanding of disease biology at the molecular level.
Refractory Disease Management
The sponsor's clinical initiatives address critical unmet medical needs in patients with treatment-refractory conditions. Research activities target patient populations who have experienced disease progression despite prior therapeutic interventions, representing a challenging segment where innovative pharmaceutical solutions are urgently needed.
- Post-Treatment Progression Interventions
- Resistant Disease Therapeutics
- Alternative Treatment Pathways
By focusing on refractory patient populations, the organization contributes to expanding therapeutic options for individuals facing limited alternatives in their disease management journey.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Phase I, Single-Blind, Placebo-Controlled Study of ABO21009 in Healthy Volunteers and Rheumatoid Arthritis Patients |  Belgium Germany The Netherlands | Recruiting |
Data & Insights
This sponsor works with 0 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 5 sites across their trial portfolio.
Therapeutic Focus
- 1.Immune System Diseases1 trial322 other sponsors
Partnered Research Centres
5 centres- Address
- Zernikedreef 8, 2333 CL Leiden
- Address
- Avenue De L'Hopital 1, 4000 Liège
- Address
- Sandhoefer Allee 1, Niederrad, 60528 Frankfurt
- Address
- Ulmenweg 18, Innenstadt, 91054 Erlangen
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Aboleris Holdco.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.